Melbourne · SSCV platform
We are entering first-in-human clinical trials for ST101, with GPI-targeting pipeline applications across global health, immunocompromised and hospital-acquired infections.
01 · Mission
Defeat the world’s deadliest infectious diseases
First-in-class synthetic saccharide conjugate vaccines (SSCV) aimed at humanity’s greatest microbial pathogens, with unprecedented potential to save lives and lower the burden of infectious diseases worldwide.
02 · Technology
Highly differentiated. Tightly protected
SSCVs targeting glycosyl-phosphatidyl-inositol (GPI). Chemically synthesised oligosaccharide conjugated to a clinically and commercially validated platform. Conserved biology, novel compositions, and expanded scope of therapeutic and prophylactic indications.
03 · Strategy
Demonstrate human feasibility, then partner
Our strategy is to conduct first-in-human and early efficacy trials, and partner with pharma for late-stage development and pipeline expansion.
04 · Pipeline
Key to unlocking our high-value pipeline
Malaria taught us all about GPI. The same target allows us to expand the scope of applications to prevent and treat diseases caused by a range of deadly pathogens, including parasites, mycobacteria, and invasive fungal infections.
Annual impact — diseases we address
300 million
cases each year
5 million
deaths each year
>100 million
DALYs of debilitation
>US $2T
global economic burden
The opportunity
Pathogens across biological kingdoms use GPI to get around our immune defences. Saccharide uses deep immunology to exploit GPI as their Achilles heel. We address diseases of interest to both specialty pharma in developed markets and global-health organisations at population scale.
Specialty pharma
Hospital-acquired and immunocompromised, invasive fungal infections. Mycobacterium avium complex (MAC) lung disease — specialty pharma, orphan incentives, $B markets, no licensed vaccines. Significant unmet medical needs and high-value pharma indications.
Global health
Two of the "Big Three" global infectious diseases. ST101 is first into the clinic, and an opportunity to demonstrate the unprecedented potential of GPI-targeting SSCVs. ST208 shows potent preclinical synergistic efficacy with BCG vs tuberculosis. Scale, access and impact — for public and private-funded global health partners, as well as premium markets for travelers, military and multinational corporations.
The target
Infections use GPI as a master modulator of our immune defences. Our SSCVs train our immune systems to neutralise these sophisticated strategies across multiple mechanisms, and the pathogens are stuck with evolutionary choices made eons ago.
The glycan component of our SSCV is chemically synthesised and presented on a clinically validated carrier. No bulk fermentation. Precise molecular definition. A scalable product, suitable for existing immunisation programs and distribution networks.
How GPI vaccines work
One GPI tether, at all stages. Compounding efficacy
01
Sporozoite invasion of the liver.
02
Parasite expansion inside hepatocytes.
03
Blood-stage replication and GPI toxin.
04
Sexual stages taken up by the mosquito.
Pipeline
ST101 · First-in-human
An SSCV directed against the GPI glycan — conserved across every Plasmodium species and life-cycle stage.
ST208 · Preclinical
An SSCV for mycobacterial infections. Synergistic in vivo efficacy with BCG vs TB, and potential in nontuberculous mycobacterial pulmonary disease in COPD — where no licensed vaccine exists.
ST300 series · Exploratory
Aspergillus, Candida and Pneumocystis — hospital-acquired and immunocompromised. Specialty pharma opportunity targeting the same GPI saccharide.
Origin
The Cairns rainforest is home to millennia of evolutionary biology — and where Distinguished Professor Louis Schofield built the Australian Institute of Tropical Health and Medicine. GPI is older than the proteins it tethers — and more fundamental. Targeting the GPI saccharide is an immunological approach with the potential to forever alter the relationship between humanity and our greatest microbial foes.
Saccharide was founded in Melbourne in 2024 to take that idea into the clinic: deep GPI immunology, chemical synthesis at clinical scale, broad-spectrum medical utility and compelling commercial potential.
Meet the foundersActive intel
We actively monitor global biotech financings and deals relevant to our pipeline.
Company news and literature
September 2026 · Biointelect
Saccharide Therapeutics is one of six Australian infectious-disease companies entering Biointelect Venturer’s inaugural incubation program. The cohort shares $10.48 million in non-dilutive support, funded through the Australian Government’s Medical Research Future Fund. ST101 was named as a glycoconjugate malaria vaccine that targets a structure conserved across Plasmodium species and life-cycle stages — with the potential for broader protection than existing vaccines.
We are entering first-in-human clinical trials for ST101 and looking for partners to accelerate progression and expansion of our pipeline.